文献速递造血干细胞移植与细胞治疗

来特莫韦预防在接受同胞全相合供者造血干细胞移植中的作用:选择合适人群以优化预防治疗

The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy.
PubMed 文献 · Br J Haematol · 2025-07-21

该回顾性研究比较72例接受来特莫韦(LTV)预防的同胞全相合造血干细胞移植受者与134例对照,LTV显著降低200天巨细胞病毒(CMV)病毒血症发生率(5.6% vs 33.3%,p<0.001);抗胸腺细胞球蛋白(ATG)使用和III-IV级急性移植物抗宿主病(aGVHD)为独立危险因素,LTV在高危患者中效果更明显,但EBV病毒血症和CD20单克隆抗体使用增加,长期生存相似。

要点

  • LTV组200天CMV病毒血症5.6% vs 对照组33.3%(p<0.001)。
  • ATG使用(p=0.005)和III-IV级aGVHD(p<0.001)为CMV病毒血症独立危险因素。
  • LTV组EBV病毒血症13.9% vs 对照组1.4%(p=0.025),CD20单抗使用11.1% vs 1.4%(p=0.046)。

核心结论

  • LTV预防显著降低同胞全相合HSCT受者的CMV病毒血症,尤其在高危患者(ATG/III-IV级aGVHD)中;但LTV组EBV相关并发症风险升高。
  • 作者认为应以风险分层而非单纯CMV血清学状态指导同胞全相合HSCT的CMV预防策略,并需更大规模临床研究验证。

研究设计与样本

  • 回顾性研究,比较72例接受LTV预防的同胞全相合HSCT受者与134例对照,结果在本中心第二队列中验证。

主要发现

  • LTV组200天CMV病毒血症发生率5.6% vs 对照组33.3%(p<0.001)。
  • 多因素分析显示ATG使用(p=0.005)和III-IV级aGVHD(p<0.001)为CMV病毒血症独立危险因素,CMV血清学状态对CMV病毒血症无显著影响(p=0.448)。
  • 按危险因素(ATG、III-IV级aGVHD)分层,LTV对高危患者的效果较低危患者更显著。
  • LTV预防与EBV病毒血症增加相关(13.9% vs 1.4%,p=0.025),CD20单克隆抗体使用更高(11.1% vs 1.4%,p=0.046)。
  • 两组长期生存相似。

临床怎么用

  • 作者认为风险分层而非单纯CMV血清学状态应指导同胞全相合HSCT的CMV预防策略。

局限性

  • 原文报告为回顾性研究。
  • 原文指出需更大规模临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Letermovir (LTV) effectively prevents cytomegalovirus (CMV) reactivation in CMV-seropositive patients. To evaluate the impact of LTV in matched sibling haematopoietic stem cell transplantation (HSCT) recipients, we retrospectively compared 72 matched sibling transplantation recipients receiving LTV with 134 controls. LTV significantly reduced 200-day CMV viraemia incidence (5.6% vs. 33.3%, p < 0.001). Multivariable analysis identified anti-thymocyte globulin (ATG) use (p = 0.005) and grade III-IV acute graft-versus-host disease (aGVHD; p < 0.001) as independent risk factors for CMV viraemia, while CMV serostatus did not significantly affect CMV viraemia (p = 0.448). Stratification based on risk factors (ATG, grade III-IV aGVHD) showed that LTV had a more significant effect on high-risk patients compared to low-risk patients. Also, LTV prophylaxis was associated with increased Epstein-Barr virus (EBV) viraemia (13.9% vs. 1.4%, p = 0.025) and higher CD20 monoclonal antibody utilization (11.1% vs. 1.4%, p = 0.046). Long-term survival remained similar between both groups. Results were validated in a second cohort from our centre. In conclusion, LTV prophylaxis significantly reduced CMV viraemia, especially in high-risk patients (ATG/grade III-IV aGVHD). However, the LTV group showed an elevated risk of EBV-related complications. Risk stratification-rather than CMV serostatus alone-should guide CMV prevention strategies in matched sibling HSCT. Larger clinical studies are needed for validation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhen S, Liu L, Liu F, et al. The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy. Br J Haematol. 2025. PMID: 40691838. doi:10.1111/bjh.70016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。